CA2383510A1 - Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction - Google Patents

Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction Download PDF

Info

Publication number
CA2383510A1
CA2383510A1 CA002383510A CA2383510A CA2383510A1 CA 2383510 A1 CA2383510 A1 CA 2383510A1 CA 002383510 A CA002383510 A CA 002383510A CA 2383510 A CA2383510 A CA 2383510A CA 2383510 A1 CA2383510 A1 CA 2383510A1
Authority
CA
Canada
Prior art keywords
antagonist
lhrh antagonist
short
induction treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383510A
Other languages
English (en)
French (fr)
Inventor
Jurgen Engel
Hilde Riethmuller-Winzen
Ricardo Felberbaum
Klaus Diedrich
Wolfgang Kupker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383510A1 publication Critical patent/CA2383510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002383510A 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction Abandoned CA2383510A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
US60/155,478 1999-09-23
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Publications (1)

Publication Number Publication Date
CA2383510A1 true CA2383510A1 (en) 2001-03-29

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383510A Abandoned CA2383510A1 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction

Country Status (22)

Country Link
EP (1) EP1214086A2 (no)
JP (2) JP2003509467A (no)
KR (1) KR100772852B1 (no)
CN (2) CN1376070A (no)
AU (1) AU769482B2 (no)
BG (1) BG66128B1 (no)
BR (1) BR0014198A (no)
CA (1) CA2383510A1 (no)
HK (1) HK1049117A1 (no)
HU (1) HUP0202741A3 (no)
IL (1) IL148185A0 (no)
MX (1) MXPA02002436A (no)
NO (1) NO331198B1 (no)
NZ (1) NZ534836A (no)
PL (1) PL201898B1 (no)
RU (1) RU2255759C2 (no)
SK (1) SK3752002A3 (no)
TR (1) TR200200738T2 (no)
TW (1) TWI267373B (no)
UA (1) UA73956C2 (no)
WO (1) WO2001021194A2 (no)
ZA (1) ZA200201374B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
DK2252627T3 (en) 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
BR112015009752A2 (pt) 2012-10-30 2017-07-11 Esperance Pharmaceuticals Inc conjugados de anticorpo/fármaco e métodos de uso
EP4223298A3 (en) 2013-03-15 2023-08-16 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
BR112020021276A2 (pt) 2018-04-19 2021-01-26 Abbvie Inc. métodos de tratamento de sangramento menstrual intenso
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
EP0769956B1 (en) * 1994-07-22 2000-03-15 The Medical College Of Hampton Roads USE OF A GnRH ANTAGONIST FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF GONADAL-STEROID CONDITIONS
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
AU729752B2 (en) * 1997-06-05 2001-02-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
NO20021430L (no) 2002-05-07
JP2003509467A (ja) 2003-03-11
JP2012051920A (ja) 2012-03-15
SK3752002A3 (en) 2003-06-03
IL148185A0 (en) 2002-09-12
BG106584A (bg) 2003-02-28
NO331198B1 (no) 2011-10-31
BR0014198A (pt) 2002-05-21
PL353244A1 (en) 2003-11-03
RU2255759C2 (ru) 2005-07-10
ZA200201374B (en) 2002-10-30
NZ534836A (en) 2007-07-27
PL201898B1 (pl) 2009-05-29
KR100772852B1 (ko) 2007-11-02
TR200200738T2 (tr) 2002-08-21
NO20021430D0 (no) 2002-03-21
HUP0202741A3 (en) 2003-12-29
WO2001021194A2 (en) 2001-03-29
MXPA02002436A (es) 2003-02-12
BG66128B1 (bg) 2011-06-30
HK1049117A1 (zh) 2003-05-02
UA73956C2 (en) 2005-10-17
TWI267373B (en) 2006-12-01
AU7779200A (en) 2001-04-24
AU769482B2 (en) 2004-01-29
EP1214086A2 (en) 2002-06-19
WO2001021194A3 (en) 2002-03-14
CN101045155A (zh) 2007-10-03
CN1376070A (zh) 2002-10-23
KR20020035879A (ko) 2002-05-15
HUP0202741A2 (hu) 2003-01-28

Similar Documents

Publication Publication Date Title
JP3130048B2 (ja) エストロゲン依存症の治療
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
Erkkola et al. Role of progestins in contraception
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
US7666836B2 (en) Method for the therapeutic management of endometriosis
JP2010539153A (ja) 閉経前の女性におけるエストロゲン依存症状の治療
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
Bedaiwy et al. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
La Marca et al. Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
Bergqvist Current drug therapy recommendations for the treatment of endometriosis
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
JP3925688B2 (ja) ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤
BR112020021565A2 (pt) Composição para tratamento de uma ou mais doenças relacionadas com estrogênio
Magyar et al. Effect of hormone replacement therapy on postmenopausal endometrial bleeding
Wong et al. Exogenous Hormone-Induced Endometrial Changes
Patel Response of the Uterus to Medication: Hysteroscopic Implications
Patel 6 Hysteroscopic Implications

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130605